Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Consistency of state statutes with the Centers for Disease Control and Prevention HIV testing recommendations for health care settings.

Mahajan AP, Stemple L, Shapiro MF, King JB, Cunningham WE.

Ann Intern Med. 2009 Feb 17;150(4):263-9. Review.

2.

Comparing the costs of HIV screening strategies and technologies in health-care settings.

Farnham PG, Hutchinson AB, Sansom SL, Branson BM.

Public Health Rep. 2008 Nov-Dec;123 Suppl 3:51-62.

3.

HIV prevalence estimates--United States, 2006.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2008 Oct 3;57(39):1073-6.

4.

Opt-out testing for human immunodeficiency virus in the United States: progress and challenges.

Bartlett JG, Branson BM, Fenton K, Hauschild BC, Miller V, Mayer KH.

JAMA. 2008 Aug 27;300(8):945-51. doi: 10.1001/jama.300.8.945.

PMID:
18728268
5.

Gaining efficiencies: resources and demand for dialysis around the globe.

Neil N, Walker DR, Sesso R, Blackburn JC, Tschosik EA, Sciaraffia V, GarcĂ­a-Contreras F, Capsa D, Bhattacharyya SK.

Value Health. 2009 Jan-Feb;12(1):73-9. doi: 10.1111/j.1524-4733.2008.00414.x. Epub 2008 Aug 1.

6.

Estimation of HIV incidence in the United States.

Hall HI, Song R, Rhodes P, Prejean J, An Q, Lee LM, Karon J, Brookmeyer R, Kaplan EH, McKenna MT, Janssen RS; HIV Incidence Surveillance Group.

JAMA. 2008 Aug 6;300(5):520-9. doi: 10.1001/jama.300.5.520.

7.

Role of budget impact in drug reimbursement decisions.

Cohen JP, Stolk E, Niezen M.

J Health Polit Policy Law. 2008 Apr;33(2):225-47. doi: 10.1215/03616878-2007-054.

PMID:
18325899
8.

Routine HIV screening in the emergency department using the new US Centers for Disease Control and Prevention Guidelines: results from a high-prevalence area.

Brown J, Shesser R, Simon G, Bahn M, Czarnogorski M, Kuo I, Magnus M, Sikka N.

J Acquir Immune Defic Syndr. 2007 Dec 1;46(4):395-401.

PMID:
18077831
9.

Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.

Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, Orlewska E, Watkins J, Trueman P.

Value Health. 2007 Sep-Oct;10(5):336-47.

10.
11.

Rapid HIV testing in emergency departments--three U.S. sites, January 2005-March 2006.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2007 Jun 22;56(24):597-601.

13.

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.

Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD; Protocol 005 Team.

Lancet. 2007 Apr 14;369(9569):1261-9.

PMID:
17434401
14.

Budget impact of Medicaid Section 1115 demonstrations for early HIV treatment.

Schackman BR, Freedberg KA, Goldie SJ, Weinstein MC, Swartz K.

Health Care Financ Rev. 2005 Summer;26(4):67-80.

15.

Detecting unsuspected HIV infection with a rapid whole-blood HIV test in an urban emergency department.

Lyss SB, Branson BM, Kroc KA, Couture EF, Newman DR, Weinstein RA.

J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):435-42.

PMID:
17224850
16.

Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.

Paltiel AD, Walensky RP, Schackman BR, Seage GR 3rd, Mercincavage LM, Weinstein MC, Freedberg KA.

Ann Intern Med. 2006 Dec 5;145(11):797-806.

PMID:
17146064
17.

Implementing an HIV and sexually transmitted disease screening program in an emergency department.

Silva A, Glick NR, Lyss SB, Hutchinson AB, Gift TL, Pealer LN, Broussard D, Whitman S.

Ann Emerg Med. 2007 May;49(5):564-72. Epub 2006 Nov 20.

PMID:
17113684
18.

The lifetime cost of current human immunodeficiency virus care in the United States.

Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, Weinstein MC, Seage GR 3rd, Moore RD, Freedberg KA.

Med Care. 2006 Nov;44(11):990-7. Review.

PMID:
17063130
19.

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.

Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, Chen SS, McColl D, Enejosa J, Toole JJ, Cheng AK.

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):535-40.

PMID:
17057609
20.

Development and verification of a "virtual" cohort using the National VA Health Information System.

Fultz SL, Skanderson M, Mole LA, Gandhi N, Bryant K, Crystal S, Justice AC.

Med Care. 2006 Aug;44(8 Suppl 2):S25-30.

PMID:
16849965

Supplemental Content

Support Center